WHOLE EXOME SEQUENCE ANALYSIS TO PREDICT FUNCTIONAL BIOMARKERS FOR PANCREATIC CANCER

Article Sidebar

PDF
Published: Aug 8, 2018
DOI: https://doi.org/10.26483/ijarcs.v9i0.6269
Keywords:
Pancreatic cancer, whole Exome Sequencing, Genomics, cancer, NGS, Sequencing

Main Article Content

Maheswari L Patil
Prof. Shivakumar B Madagi
Dr. C. N. Prashantha

Abstract

NGS is commonly called as massive-parallel sequencing, a technology that enabled genome to be sequenced efficiently. One of the applications of NGS is Whole exome sequencing that proves to be an effective method to to detect disease-causing variants and discover gene targets. Using whole exome sequencing data it is possible to identify clinical interventions of differentially expressed genes, somatic variants and targeted pathways to develop and assess the efficacy of novel therapies. The current work used pancreatic cancer genome sequencing data to predict significant gene variants by using exome sequencing data analysis. Here predicted 934 gene mutations identified by Exome-seq were validated by mRNA-seq. Further focused on gene expression and predicted 914 genes are differentially expressed that covers mRNA-sequences. There are 20 mutations such as HRNR, MERTK, RPL14, GLT6D1, NEO1, ZNF208, ZNF226, DNAH9 and SEZ6L is significantly involved in different pathways that integrated insulin secretion with in islet cells of pancreas and also involved in diabetes mellitus. Based on gene mutations, it is possible to screen the drugs based on pharmacogenomic characters that are functionally involved in pancreatic cancer pathways. These observations provide genetic predictors of outcome in pancreatic cancer and have implications for new avenues of therapeutic intervention.


Downloads

Download data is not yet available.

Article Details

Issue
2018: Volume 9 Special Issue No. 3, May 2018
Section
Articles

COPYRIGHT

Submission of a manuscript implies: that the work described has not been published before, that it is not under consideration for publication elsewhere; that if and when the manuscript is accepted for publication, the authors agree to automatic transfer of the copyright to the publisher.

Authors who publish with this journal agree to the following terms:

  • Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
  • Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
  • Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work
  • The journal allows the author(s) to retain publishing rights without restrictions.
  • The journal allows the author(s) to hold the copyright without restrictions.

References

Li J., Wientjes, M. G., and Au, J. L.-S. 2010. Pancreatic Cancer: Pathobiology, Treatment Options, and Drug Delivery. The AAPS Journal, 12(2): 223–

[2] Khanal N., Upadhyay, S., Dahal, S., Bhatt, V. R., & Silberstein, P. T. 2015. Systemic therapy in stage IV pancreatic cancer: a population-based analysis using the National Cancer Data Base. Therapeutic Advances in Medical Oncology, 7(4): 198–205. [3] Michel M. Murr, Michael G. Sarr, Andrew J. Oishi, Jon A. van Heerden. 1994. PancreaticCancer. CA: A Cancer Journal for Clinicians, 44(5): 304-3018. [4] Fang, Y., Yao, Q., Chen, Z., Xiang, J., William, F. E., Gibbs, R. A., & Chen, C. 2013. Genetic and molecular alterations in pancreatic cancer: Implications for personalized medicine. Medical Science Monitor : International Medical Journal of Experimental and Clinical Research, 19: 916–926. [5] Qiubo Zhang, Linjuan Zeng, Yinting Chen, et al. 2016. Pancreatic Cancer Epidemiology, Detection, and Management. Gastroenterology Research and Practice, 2016. [6] Winter, J. M., Maitra, A., & Yeo, C. J. 2006. Genetics and pathology of pancreatic cancer. HPB : The Official Journal of the International Hepato Pancreato Biliary Association, 8(5): 324–336 [7] Maitra, A., & Hruban, R. H. 2008. Pancreatic Cancer. Annual Review of Pathology, 3: 157–188. [8] Dong, X., Li, Y., Hess, K. R., Abbruzzese, J. L., & Li, D. 2011. DNA Mismatch Repair Gene

Maheswari L Patil et al, International Journal of Advanced Research in Computer Science, 9 (Special Issue III), May 2018, 361-367

Conference Paper: Third National Conference on “Advances in Computing and Information Technology†Organized by: School of Computing and Information Technology, REVA University, Bengaluru, India 367

Polymorphisms Affect Survival in Pancreatic Cancer. The Oncologist, 16(1): 61–70. [9] Miura, F., Takada, T., Amano, H., Yoshida, M., Furui, S., & Takeshita, K. 2006. Diagnosis of pancreatic cancer. HPB : The Official Journal of the International Hepato Pancreato Biliary Association, 8(5):337–342. [10] Reynolds, R. B., & Folloder, J. 2014. Clinical Management of Pancreatic Cancer. Journal of the Advanced Practitioner in Oncology, 5(5): 356–364. [11] Raza, K., & Ahmad, S. 2016. Principle, analysis, application and challenges of next-generation sequencing: a review. arXiv preprint, arXiv:1606.05254. [12] Gagan and Van Allen.2015. Next-generation sequencing to guide cancer therapy. Genome medicine, 7:80. [13] Buermans H.P.J., J.T. den Dunnen. 2014. Next generation sequencing technology: Advances and applications, Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease; 1932–1941. [14] Yadong Yang, Xunong Dong, Bingbing Xie, Nan Ding, Juan Chen, Yong jun Li, et al. 2015, Databases and Web Tools for Cancer Genomics Study Genomics, Proteomics & Bioinformatics 13(1):46-50. [15] Lynda Chin, William C, Hahn, Gad Getz and Matthew Meyerson. 2011 Making sense of cancer genomic data. Genes and Development,Cold Spring Harbor Laboratory Press, 5: 534–555 [16] Matan Hofree, Hannah Carter, Jason F. Kreisberg, Sourav Bandyopadhyay, Paul S. Mischel,Stephen Friend Trey . Ideker. 2016. Challenges in identifying cancer genes by analysis of exome sequencing data. Nature Communications, 7:12096. [17] Bao et al. 2014. Review of Current Methods, Applications, and Data Management for the

Bioinformatics Analysis of Whole Exome Sequencing. Cancer Informatics, 13(S2): 67–82 . [18] Bahareh Rabbani, Mustafa Tekin and Nejat Mahdieh. 2014. The promise of whole-exome sequencing in medical genetics. Journal of Human Genetics 59(5):15. [19] Andrews S. FastQC. Babraham Bioinformatics; Cambridge, UK. 2012. Available from https://www.bioinformatics.babraham.ac.uk/projects/f ast qc. [accessed 11 December 2017] [20] Martin M. 2011. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet J, 17:10–2. [21] Bolger AM, Lohse M, Usadel B. 2014, Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics, 30(15):2114–20. [22] Langmead B. and S. L. Salzberg. 2012. Fast gapped- read alignment with Bowtie 2. Nature Methods, 9(4):57– 359, [23] Li H., B. Handsaker, A. Wysoker et al. 2009. The Sequence Alignment/Map format and SAMtools. Bioinformatics, 25(16): 2078–2079. [24] Takeshi Ogasawara, Yinhe Cheng, Tzy-Hwa Kathy Tzeng. Sam2bam: High-Performance Framework for NGS Data Preprocessing Tools. arXiv:1608.01753 [q- bio.GN] [25] McKenna. A, M. Hanna, E. Banks et al. 2010. The genome analysis toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Research, 20(9): 1297–1303, 2010. [26] Huang D. W., B. T. Sherman, and R. A. Lempicki. 2009. Bioinformatics enrichment tools: paths towards the comprehensive functional analysis of large gene lists. Nucleic Acids Research, 37(1): 1–13.